Sonoma Pharmaceuticals Shares Up After Launch of First Over-the-Counter Products in the U.S. on Amazon

Sep 28, 2021 By MarketDepth

Biotechnology Healthcare What's Hot

Stock Jumps

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) stock jumped more than 34% after the Company has announced the over-the-counter (“OTC”) consumer launch of Regenacyn® Advanced Scar Gel and Ocucyn® Eyelid & Eyelash Cleanser on, and MucoClyns™ on Amazon sites in Europe. All three products are based on Sonoma’s patented Microcyn® technology and are immediately available for customer orders.

Line of Healthcare Products

Sonoma Pharmaceuticals develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. 

Product to Improve Scars

Regenacyn Advanced Scar Gel is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness and inflammation. Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.

“we could not be more excited about making our safe and effective products available directly to consumers through Amazon. We look forward to offering our clinically proven and patented Microcyn® Technology to a wider range of patients for advanced scar management, eyelid & eyelash hygiene and personal protection spray for the face and skin.”

Amy Trombly, Chief Executive Officer of Sonoma Pharmaceuticals